New spatial tumor mapping tool to assess cancer aggressiveness and personalize treatment
aiFRET quantifies HIF1β/HIF2α and PD-1/PD-L1 interactive states in ccRCC patients. The upper panel illustrates HIF1β/HIF2α expression. HIF1β is the donor ...
Tag: aggressiveness
